|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM072321687 |
| 003 |
DE-627 |
| 005 |
20231222013951.0 |
| 007 |
tu |
| 008 |
231222s1981 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0241.xml
|
| 035 |
|
|
|a (DE-627)NLM072321687
|
| 035 |
|
|
|a (NLM)7255512
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Stuart, J J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Choline magnesium trisalicylate does not impair platelet aggregation
|
| 264 |
|
1 |
|c 1981
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.09.1981
|
| 500 |
|
|
|a Date Revised 19.11.2015
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Blood platelet aggregation in response to adenosine diphosphate (ADP), epinephrine or collagen stimulation was measured in 9 mainly arthritic patients continually treated with choline magnesium trisalicylate for an average of 11 months. Aggregation was entirely normal in 5 of the subjects and only minimally reduced in 3 who showed suppression, in 2 cases borderline or minimal, of ADP-induced aggregation only; the reasons were unclear and the possibility of pre-treatment subnormal responses to ADP, in this group, could not be ruled out. The ninth subject showed no secondary wave of aggregation with ADP or epinephrine and only 21% aggregation with collagen, findings typical of aspirin use. She was thought to have ingested this drug unknowingly and to warrant exclusion from the evaluation. It is concluded that protracted use of choline magnesium trisalicylate does not interfere with platelet aggregation under the conditions of this study. The results obtained were consistent with the reported failure of this drug to cause significant faecal blood loss in clinical trials
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents
|2 NLM
|
| 650 |
|
7 |
|a Salicylates
|2 NLM
|
| 650 |
|
7 |
|a Adenosine Diphosphate
|2 NLM
|
| 650 |
|
7 |
|a 61D2G4IYVH
|2 NLM
|
| 650 |
|
7 |
|a choline magnesium trisalicylate
|2 NLM
|
| 650 |
|
7 |
|a DJJ95FJP1H
|2 NLM
|
| 650 |
|
7 |
|a Choline
|2 NLM
|
| 650 |
|
7 |
|a N91BDP6H0X
|2 NLM
|
| 700 |
1 |
|
|a Pisko, E J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 2(1981), 8 vom: 16., Seite 547-51
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:2
|g year:1981
|g number:8
|g day:16
|g pages:547-51
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 2
|j 1981
|e 8
|b 16
|h 547-51
|